Halofantrine-associated ventricular fibrillation in a young woman with no predisposing QTc prolongation

Scandinavian Journal of Infectious Diseases

Volumn 29, Issue 2, 1997, Pages 207-208

  Gundersen, Svein Gunnar ^a,c   Rostrup, Morten ^a   Von Der Lippe, Elisabeth ^a   Platou, Eivind S ^a   Myrvang, Bjoern ^a   Edwards, Geoffrey ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CHLORAMPHENICOL; CHLOROQUINE; HALOFANTRINE; METRONIDAZOLE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG BLOOD LEVEL; FEMALE; HEART VENTRICLE FIBRILLATION; HUMAN; MALARIA FALCIPARUM; QT INTERVAL;

EID: 0030969064     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365549709035889     Document Type: Article

References (14)

1. ter Kuile FO, Dolan G, Nostern F, Edstein MD, Luxemburger C, Phaipun L, Chongsuphajaisiddhi T, Webster HK, White NJ. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet 341: 1044-1049, 1993.
2. Nosten F, ter Kuile FO, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, White NJ, Cardiac effect of antimalarial treatment with halofantrine. Lancet 341; 1054-1056, 1993.
3. Karbwang J, Bangchang K Na, Bunnag D, Harinasuta T. Cardiac effect of halofantrine [Letter]. Lancet 342: 501, 1993.
4. Castot A, Rapoport P, le Coz P. Prolonged QTc interval with halofantrine [Letter]. Lancet 341: 1541, 1993.
5. Monlun E, Le Metayer P, Szwandt S, Neau D, Longy-Boursier M, Horton J, Le Bras M. Cardiac complications of halofantrine: a prospective study of 20 patients. Trans Roy Soc Trop Med Hyg 89: 430 433, 1995.
6. Touze JE, Bernhard J, Keundjiran A, Imbert P, Viguier A, Chaudet H, Doury JC. Electrocardiographic changes and halofantrine plasma level during acute falciparum malaria. Am J Trop Med Hyg 54: 225-228, 1996.
7. Matson PA, Luby SP, Redd SC, Rolka HR, Meriweter RA. Cardiac effects of standard-dose halofantrine treatment. Am J Trop Med Hyg 54: 229 231, 1996.
8. Monlun E, Leenhardt A, Pillet O, Gaston R, Receveur MC, Bouabdallah K, Longy-Boursier M, Favarel-Garrigues JC, Le Bras M. Arythmies ventriculaires at prise d'halofantrine. Bull Soc Path Ex 86: 365-368, 1993.
9. Toivonen L, Viitasalo M, Siikamäki H, Raatikka M, Pohjola-Sintonen S. Provocation of ventricular tachycardia by antimalarial drug halofantrine in congenital long QTc syndrome. Clin Cardiol 17: 403-404, 1994.
10. Bradley D. Letter to the Editor. Br Med J 308: 721, 1994.
11. Mberu EK, Muhia DK, Watkins WM. Measurement of halofantrine and its major metabolite desbutylhalofantrine in plasma and blood by high-performance liquid chromatography: a new methodology. J Chromatogr 581: 156 160, 1992.
12. Milton KA, Edwards G, Ward SA, Orme ML'E, Breckenridge AM. Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmac 28: 71 77, 1989.
13. Karbwang J, Bangchang KN. Clinical pharmacokinetics of halofantrine. Clin Pharmacokinet 27: 104 119, 1994.
14. Heinzel G, Woloszczak R, Thomann P. Topfit Version 2.0; Pharmacokinetic and pharmacodynamic data analysis system for the PC. Gustav Fisher Verlag, Stuttgart, Germany, 1992.